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Abstract: The main goal of the present study is to examine to what extent age and cognitive 
impairment contribute to learning performance (cognitive plasticity, cognitive modifiability, or 
learning potential). To address this question, participants coming from four studies (Longitudinal 
Study of Active Aging, age range, 55–75 years, N = 458; Longitudinal Study in the very old 
[90+], age range, 90–102, N = 188, and Cognitive Plasticity within the Course of Cognitive 
Impairment, 97 “Normal”, 57 mild cognitive impairment [MCI], and 98 Alzheimer’s disease 
[AD] patients) were examined through a measure of verbal learning (developed from Rey). The 
results show that all age, MCI, and AD groups learned across the five learning trials of that 
test, but significant differences were found due to age, pathology, and education. The effects 
of pathology (MCI and AD) can be expressed in a metric of “years of normal decline by age”; 
specifically, being MCI means suffering an impairment in performance that is equivalent to the 
decline of a normal individual during 15 years, whereas the impact of AD is equivalent to 22.7 
years. Likewise, the improvement associated with about 5 years of education is equivalent to 
about 1 year less of normal aging. Also, the two pathological groups significantly differed from 
“normal” groups in the delayed trial of the test. The most dramatic difference is that between 
the “normal” group and the AD patients, which shows relatively poorer performance for the 
AD group in the delayed trial than in the first learning trial. The potential role of this unique 
effect for quick detection purposes of AD is assessed (in the 75–89 years age range, sensitivity 
and specificity equal 0.813 and 0.917, respectively).
Keywords: cognitive plasticity, cognitive modifiability, learning age, aging, Alzheimer’s disease, 
mild cognitive impairment
Introduction
Cognitive aging research shows a clear picture characterized by a gradual decline in 
function over time, starting early in life.1–4 From the last decades of the 20th century, 
learning potential,5 cognitive modifiability,6 or cognitive plasticity across the aging 
process (also called reserve capacity or testing-the-limit) has been a central issue in 
gerontology since a stereotypic trait in general population said that “older people are 
unable to learn.”7 Cognitive plasticity is operationalized as the extent to which an 
individual can improve his/her performance in a given cognitive task through training 
(this procedure has also been called “dynamic assessment” as opposed to the standard 
“static” measures of cognitive functioning).8–12 Although cognitive plasticity measures 
seem to be preserved during normal aging, many authors agree that they are associ-
ated with age; in other words, cognitive plasticity measures have shown a profile of 
decline in most of the studies.13
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In order to examine plasticity (through episodic memory 
tasks), Singer et al14 trained a mnemonic skill to survivors of 
the Berlin Aging Study (N = 96; mean age, 84 years; range, 
75–101 years). Gains after mnemonic training were modest 
and most individuals were unable to improve their perfor-
mance after training; the authors concluded that in very old 
age, “biological factors are a prominent source of individual 
differences in plasticity.”
Taking as a basis these and other results, Baltes and 
Smith15 considered that the oldest-old, called the “fourth age,” 
“entails a level of biocultural incompleteness, vulnerability, 
and unpredictability that is distinct from the positive views 
of the third age (young-old)”; the authors concluded that the 
oldest-olds are at the limits of their functional capacity.
Nevertheless, a somewhat different conclusion was 
reached by Yang et al,16 using a self-guided retest paradigm. 
This paradigm allows the study of a basic form of cognitive 
plasticity, called retest learning, as reflected in improvements 
of performance through retest practice in five trials. They 
investigated whether cognitive plasticity could be extended 
from the young-old to the oldest-old. The results showed 
evidence for continued plasticity until age 80 and above; 
substantial improvements in performance, comprising one 
standard deviation from the pre-test to the sixth trial, were 
observed.
However, research on cognitive functioning in individuals 
aged 65–90 years who have abnormal memory function-
ing, but do not meet formal criteria for the diagnosis of 
dementia, supported Petersen’s proposal that the syndrome 
Mild Cognitive Impairment (MCI) seems to be a transition 
between normal aging and dementia.17 As the author claims: 
“The concept of the boundary between normal aging and 
early Alzheimer’s disease is a focus of a great deal of research 
in the field of aging and dementia.” In an attempt to deter-
mine whether MCI occurred in the oldest-old and whether 
neuropsychometric performance based on clinical diagnosis 
was working well in this age group, Boeve et al18 examined 
with neuropsychometric testing a sample of individuals aged 
90–100 years (N = 111). Results yielded 56 normal (50.45%), 
13 MCI (11.7%), and 42 with dementia (37.8%). The authors 
concluded that it was possible to observe the full cognitive 
continuum from normal to MCI to dementia in the oldest-old, 
but it is important to emphasize that they found significant 
differences only between the MCI and normal groups in 
delayed recall. Individuals with MCI were more similar to 
normal than to patients with dementia.
On the other hand, cognitive plasticity is severely 
impaired in individuals with dementia, as Baltes and her 
group pointed out,2,19 the assessment of cognitive plastic-
ity (or cognitive reserve capacity) could be a tool for early 
diagnosis of dementia and an expression of cognitive reserve. 
In the context of the Berlin Aging Study, Lindenberger 
and Reischies20 reported the results obtained through the 
Enhanced Cued Recall (ECR) test administered among 
several neuropsychological tests with the purpose of identi-
fying dementia-specific cognitive impairments and learning 
potential. Six groups were distinguished: three age groups 
(N = 162; mean ages, 74.9, 84.7, and 94.5 years) and three 
groups with dementia patients (Mild, N = 32; Moderate, 
N = 30; Severe, N = 31). Persons without dementia showed 
a decreased level of performance in learning as age advanced 
but no significant differences were found in learning gains. In 
comparison with persons with dementia they found signifi-
cant differences, both in performance levels and in learning 
gains. Within the dementia subsample, individuals with 
mild dementia differed from those with moderate or severe 
dementia with respect to both performance level and learning 
gain; only those patients with mild dementia obtained simi-
lar learning gains than the oldest “normal” groups. In sum, 
the results indicated that age and dementia had dissociable 
effects on the recall level and learning gains. Mild dementia 
patients showed a reduction in performance but they were 
capable of improvement in the post-test. Finally, individuals 
with moderate and severe dementia not only showed lower 
levels of initial recall performance, they did not show any 
gain after training.
During the last years we have studied cognitive plasticity 
(or learning potential) in healthy, MCI individuals, and mild 
Alzheimer’s disease (AD) patients. In our studies, cognitive 
plasticity was assessed through test-training-retest strategy 
administering several cognitive tasks (visuo-spatial   memory, 
audio-verbal memory, executive function, and verbal 
  fluency), among them the Verbal Memory Learning Potential 
test21 (VMLPt, developed based on the “verbal learning test” 
from Rey).1 Cognitive plasticity was assessed in three groups 
of older individuals: healthy (N = 100), MCI (N = 50), and 
AD patients (N = 50). In all tasks the three groups, similar 
in age and education, improved their performance when 
training was provided in each task, but healthy elders sig-
nificantly obtained higher pre-test, post-test, and gain scores 
than the MCI and AD groups did. There was a gradient of 
modifiability from healthy to MCI and from MCI to AD, but 
it must be emphasized that mild AD patients benefited from 
training as well. Finally, the total score of cognitive plastic-
ity correctly classified 89% of Healthy, MCI individuals, 
and AD patients, and it did better than other tests such as 
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the Mini Mental State Examination (MMSE).23 In sum, two 
important findings resulted from this study: (1) Although 
healthy individuals significantly showed better scores in 
all cognitive plasticity measures, both MCI individuals and 
mild AD patients were able to learn, that is, they improved 
their performance after training in those four cognitive tasks 
(dots memory, verbal memory, executive function, and verbal 
fluency),21 and (2) AD patients improved their performance 
in cognitive plasticity measures after 6 months of a psycho-
stimulation program.24
Most of the studies in cognitive plasticity have 
been conducted in Western countries, where the level 
of education is quite high even in the oldest cohort. 
  Nevertheless, in a previous study, Fernández-Ballesteros 
and Calero25 found significant differences in learning 
potential (  cognitive plasticity) between elders with high 
and low levels of education. The effect of education in 
crystalized intelligence is very well known;26 on the clini-
cal field, lack of education is considered a risk factor for 
accelerated memory decline, on the contrary education is 
considered a protective factor for cognitive impairment 
and dementia.27,28 For example, Schmand et al29 examined 
the decline across life span in the population density of 
neocortical synapses which do not reach the level found by 
AD patients. Also, they examined the broad effect of edu-
cation in rising neocortical synaptic density; finally, after 
considering aging population projections, they concluded 
that it is important to protect cortical synapses through 
cognitive stimulation across life span. This panorama 
make education as a compensator and/or a protective factor 
for cognitive impairment.
In sum, cognitive plasticity seems to be a relatively 
new construct yielding useful information about   normal 
and impaired mental functioning being influenced   
by age, level of pathology, and education. After this 
review, an important question remains: to what extent 
are age and pathology accounting for cognitive decline 
and/or impairment? Thus, considering the growing inter-
est in the oldest-old and the relevance and increasing 
prevalence of cognitive impairment, dementia due to AD 
through very old age, the present article addresses three 
main questions: (1) to what extent cognitive plasticity is 
preserved but decline across different ages, including the 
very old, and to what extent this decline is mediated by 
education; (2) to what extent do MCI individuals and mild 
Alzheimer’s disease patients maintain a gradient of modifi-
ability; and (3) to what differential extent age, pathology, 
and   education influence plasticity.
Methods
Participants
The total sample came from four different research projects:
“Normal” older adults, 55–89 years old
From the baseline of the ELEA Project (Longitudinal Study 
of Active Aging),30 in which people were assessed in the year 
2006, individuals from 55 to 74 years of age were recruited. 
The criterion for inclusion in this population study was 
being in the age range 55–75 years. In order to have a varied 
sample, convenient subsamples were recruited from four 
contexts (a representative sample of the Madrid population, 
rural and urban citizen clubs, and a university program for 
the elderly).
Participants aged 75–89 years were assessed in 2002 from 
the Learning Potential Study (LPS).21 In this clinical study, the 
criteria for inclusion of “normal” older sample were: absence 
of central nervous system pathological conditions and other 
health problems related to cognitive impairment (alcoholism, 
drug addiction, or systemic diseases, etc).
Therefore, a total of 601 participants 55–89 years old 
were included in the present study (mean age, 68.8 years; 
SD = 6.6; range, 55–89; 347 females and 254 males; mean 
years of education, 8.9 years; SD = 9.4)
“Normal” oldest-old, older than 90 years old
From the baseline of the “90+” Longitudinal Project, assessed 
during 2007, the data from 188 participants older than 90 years 
(mean age, 92.9; SD = 2.5; age range, 90–102; years of educa-
tion, 9.3 years; SD = 14.5) were re-analyzed (all of them were 
born before 1917; 121 females and 67 males). The criteria for 
inclusion for this population study were the following: $90 
years old, independence in basic activities of daily living (score 
. 60 on the Barthel scale),31 and having preserved cognitive 
capacity (score . 56 in the Informant Questionnaire of Cogni-
tive Impairment on the Elderly or have less than two errors in 
the Sort Portable Mental Status Questionnaire (SPMSQ)32 or 
less than three if the level of education is low). This is also a 
convenience sample, recruited from several contexts.
It is important to mention that our “normal” age groups 
significantly differed (χ2[24] = 56.43, P , 0.001) in their 
level of education; younger cohorts had higher levels of 
education than older cohorts. These differences correspond to 
population differences in those cohorts due to socio-historical 
changes in the education system in Spain.33
Table 1 shows how the “normal” sample is distributed 
for age groups (55–64; 65–69; 70–74; 75–89; 90+ years) 
and gender.
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 “Mild Cognitive Impairment” and Alzheimer’s  
disease patients
From the baseline of the Longitudinal Project “Cognitive 
Plasticity during the Course of Dementia CPCD” (baseline in 
2007) data from 57 individuals diagnosed as “Mild   Cognitive 
Impairment” (MCI; mean age, 76.11 years; SD = 5.20; range, 
65–86 years) and 98 patients (mean age, 78.16; SD = 5.07; 
range, 64–88) diagnosed with Alzheimer’s disease (“mild” 
AD) were re-analyzed. Table 2 shows the sample distribu-
tion by gender and age. Regarding education, no significant 
differences between groups were found; the mean years of 
education were 10.46 years for the MCI group (SD = 12.7) 
and 7.16 years for the AD group (SD = 5.32).
 MCI individuals were diagnosed in the Diagnostic Unit of 
the ACE Centre by independent experts according to the crite-
ria from Petersen et al:34 memory complaints, normal activities 
of daily living, normal general cognitive function, abnormal 
memory for age, and do not follow dementia criteria.
AD patients were included according to the criteria 
from the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV);35 criteria from the 
National Institute of Neurological and Communicative 
Disorders and Stroke-Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA; Protocol 
Attachment HGIV .3);36 a Mini Mental State Examination 
(MMSE)37 score 18–26 or a level 4 score in the Global 
Deterioration Scale (GDS);38 a Hachinski Scale score39 #4. 
Informed consent from a close relative was required. 
Subjects with psychiatric illness or primary neurological 
disorder or delirium, or with alcoholism or drug addiction 
history were excluded.
Instruments and procedures
In order to assess cognitive plasticity, all participants were 
evaluated under standard conditions by the Verbal Memory 
Learning Potential test VMLt (based on the “verbal learning 
test” from Rey;22,40 modified by Fernández-Ballesteros et al).21 
The task consisted of the auditory presentation of 15 common 
words which were to be immediately recalled (free recall). 
The number of words correctly recalled in the first trial was 
considered the pre-test score or baseline. Afterwards, five 
consecutive learning trials were performed using the same 
words; after the second, third, and fourth trials, feedback 
(number of words correctly recalled) and verbal reinforce-
ment were provided (“good!; you did very well!”); in the 
fifth trial, a cognitive strategy (verbally described: “perhaps 
you can group the words”) was suggested. Trials 2–5 were 
considered the training phase. The sixth trial was considered 
the post-test. Finally, after the presentation of an interference 
task, delayed recall was included (seventh trial). The number 
of words correctly recalled in each trial was considered the 
raw score.
In all the studies, VMLt instructions were the same 
being administered for a trained psychologist expert on 
aging. In the two population studies (ELEA and 90+), the 
VMLt was placed inside an in-home interview, interference 
phenomena was a four-item Wellbeing Scale; in the two 
clinical studies (LPS and CPCD), the VMLt was placed 
into a Cognitive Battery, interference phenomena was a 
dots task.
Statistical analysis
In order to examine group differences (age group and 
  pathology) among scores through trials, t-tests and between 
and/or repeated measures analysis of variances (ANOVAs) 
were conducted with post-hoc Bonferroni comparisons, when 
appropriate. ANOVAs were performed in order to test the 
effects of the level of education with the age groups. Finally, 
the relative weights of age and pathology group performance 
were assessed via logistic regression. Statistical analyses 
were carried out using SPSS software (v 15.0; SPSS, Inc, 
Chicago, IL).
Results
We first analyzed the learning performance of “normal” 
participants, and then we compared their performance to that 
of the pathological groups.
Table 1 “Normal” age groups by gender
Age group (years) Gender
Male Female Total
55–64 57 98 155
65–69 70 96 166
70–74 76 107 183
75–89 51 46 97
90+ 67 120 187
Total 321 467 788
Table 2 Composition of the pathology groups (MCI and AD) 
according to gender and age group
Age group (years) Gender
55–64 65–69 70–74 75–89 Male Female
MCI 
(N = 57)
0 7 14 36 28 29
AD 
(N = 98)
2 4 17 75 57 41
2 11 31 111 85 70
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease.
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Performance of the “normal” group
Figure 1A shows performance levels of the “normal” partici-
pants, according to their age group. A 5 × 7 ANOVA (five 
between-group age levels, seven within-subject trials) was 
applied to the values (it could be argued that trial 7 is qualita-
tively different from the other six, and should not be included 
in this analysis; when repeated with only the first six trials, 
the pattern of results did not change in this group nor in the 
equivalent analyses for the other groups, in the sense that the 
same factors remained significant). There was a significant 
main effect of the age group (F [4,715] = 127.0; P , 0.001) 
and the trial (F [6,4290] = 812.6; P , 0.001). As revealed 
in the figure, performance was inversely related to age, and 
performance monotonically increased along the first six trials 
but decreased in the delayed trial (seventh trial). The inter-
action was also statistically significant (F [24,4290] = 15.3; 
P , 0.001); again, the functions in Figure 1A show that the 
rate of performance increase as a function of the trial number 
(until trial 6) was slower as age increased. When years of 
education was included as a covariate it explained a signifi-
cant part of the variance (F [1,669] = 35.5; P , 0.001), and 
the interaction of trial number by years of education was also 
significant (F [6,4014] = 2.9; P = 0.01). However, the effects 
highlighted in the analysis above (age group, trial number, 
and the age group by trial interaction) remained significant 
when years of education was included as a covariate. Of 
course, years of education was positively associated with 
performance; performance was higher with increasing years 
of education.
Regarding trial 7, the delayed recall trial, Figure 1A shows 
that all age groups demonstrated a decline. Although a one-
way ANOVA of the five age groups on the differences (T6-T7) 
reached statistical significance (F [4,768] = 2.4; P = 0.048) 
there was no systematic pattern in the differences associated 
with age group. Bonferroni post-hoc comparisons showed 
that only one pair (55–64 versus 70–74 age groups) from 
ten possible comparisons differed significantly (P = 0.032). 
The result of this ANOVA is interpreted as a probable type 
I error, and we conclude that there is no systematic associa-
tion between age and the amount of decline of performance 
in the delayed trial.
The upper panel of Table 3 shows some specific com-
parisons of special interest to our purpose here: gain across 
the six trials (T6-T1), and decrease in the delayed trial as 
compared with the level reached in the sixth trial (T6-T7). 
Performance level at the first trial (T1) was compared across 
the groups by means of an ANOVA that showed a significant 
effect (F [4,779] = 65.8; P , 0.001)
Figure 1A shows that, as expected, performance 
decreased monotonically as a function of age. Bonferroni 
post-hoc comparisons show significant differences between 
all pairs of age groups (P , 0.05) with two exceptions: 65–69 
versus 70–74 and 70–74 versus 75–89.
MCI group
Figure 1B shows the performance levels of the MCI group 
according to their ages. A 2 × 2 × 7 ANOVA (two pathology 
between-groups – normal versus MCI, two between-group 
age levels, seven within-subject trials) was applied to the 
values (only the two age groups of 70–74 and 75–89 were 
included, given the small size of the 65–69 age group). 
There was a significant main effect of the pathology group 
(F [1,365] = 54.5; P , 0.001), the age group (F (1,365) = 4.8; 
P , 0.03), and the trial number (F [6,2190] = 275.1; 
P , 0.001); as revealed in the figure performance was lower 
for the MCI group than for normal participants, performance 
monotonically increased along trials 1–6 and decreased in the 
delayed (seventh) trial, and performance was worse for the 
older group. The first-order interaction between the pathol-
ogy group and the trial was significant (F [6,2190] = 37.3; 
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Figure 1 Learning performance on (A) healthy elders, (B) MCI individuals, and (C) AD patients. The mean number of words correctly recalled (y-axis) is plotted as a function 
of the trial (1–7 in the x-axis), for each age group. The first trial is considered as the baseline, whereas trials 2–5 are the training phase, and trial 6 is considered the post-test; 
the 7th trial is a delayed trial performed (see the text).
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease.
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P , 0.001); the functions in Figure 1A and B show that the 
rate of performance increase as a function of trial was slower 
for the MCI group. However, the first-order interactions of 
age group were not significant, neither with trial number 
(F [6,2190}) = 0.524; P = 0.79), or the pathology group   
(F [1,365] = 0.675; P = 0.412); in the same vein, the second-
order interaction (pathology group by age group by trial) was 
not significant (F [6,2190] = 0.437; P = 0.854).
In the previous section a significant interaction between 
age and trial was found. However, Figure 1A suggests that it 
could be due to the extreme age groups (55–64 and 90+) that 
were not present in the MCI group. Repeating the ANOVA of 
the previous section for the normal participants, with only the 
two age groups with enough data in the MCI group (70–74 
and 75–89), it was found that the interaction between trial and 
age group was not significant (F (6,1374) = 1.4; P = 0.214). 
That is, the interaction of the previous analysis was due to 
the extended range of age groups.
When adding years of education as a covariate, a signifi-
cant increase in the variance was explained (F [1,219] = 6.6; 
P = 0.011), and the interaction with trial was not significant 
(F [6,1314] = 0.79; P = 0.579). However, the effects high-
lighted (pathology group, age group, trial, and pathology by 
trial interaction) remained significant when the covariate was 
years of education.
For the decline of performance as a dependent vari-
able (difference between performance in the last learning 
trial and the delayed trial, T6-T7), a 2 × 2 ANOVA (two 
pathology groups, two age groups) was performed. The 
results showed no significant effect of the main factor age 
group (F [1,359] = 1.27; P = 0.261), nor of the interaction 
(F [1,359] = 1.58; P = 0.209), but a significant effect of the 
pathology group (F [1,359] = 28.0; P , 0.001). The decline 
was significantly greater for the MCI group than for the 
normal subjects (2.81 versus 1.62, on average).
The middle panel of Table 3 shows the specific compari-
sons for the MCI age groups for which there were enough 
participants. Again, the two age groups showed significant 
gains and delayed decrease. Furthermore, alongside the first 
trial performance, a 2 × 2 ANOVA (two pathology groups, 
two age groups) was performed. It showed nonsignificant 
effects of pathology group (F [1,369] = 1.62; P = 0.424), 
the group (F [1,369] = 2.96; P = 0.335), and the interaction 
(F [1,369] = 2.69; P = 0.102).
In short, the results showed that when taking normal 
subjects of a wide age range, level of performance changes 
significantly as a function of age. The MCI group showed 
a level of performance comparable to that of the normal 
subjects in the first trial. However, the learning curves show 
slower rates of improvement for the MCI subjects, and a 
larger decrease in the delayed trial. Although the slope of 
the learning curve across age was smaller for the MCI group, 
this interaction was not significant.
AD group
Figure 1C shows the performance levels of the AD group, 
according to their age group; data were only available 
for subjects from the 70–74 and 75–89 age groups. Some 
analyses comparing the two pathological groups were run. 
A 2 × 2 × 7 ANOVA (two pathology between-group, two 
between-group age levels, seven within-subject trials) was 
Table 3 Learning comparison in gain score (Trial 6–Trial 1) and 
delayed scores (Trial 6–Trial 7), t-test
Group Age group 
(years)
Comparison Mean diff
Normal 55–64 T6-T1 5.85 t(154) = 29.85;   
P , 0.001
T6-T7 1.02 t(154) = 6.82; 
P , 0.001
65–69 T6-T1 5.46 t(165) = 32.48;   
P , 0.001
T6-T7 1.26 t(165) = 8.61;  
P , 0.001
70–74 T6-T1 5.59 t(181) = 29.70;   
P , 0.001
T6-T7 1.63 t(180) = 12.19;   
P , 0.001
75–89 T6-T1 5.28 t(96) = 22.39;  
P , 0.001
T6-T7 1.51 t(95) = 8.09;  
P , 0.001
$90 T6-T1 3.08 t(172) = 18.01;   
P , 0.001
T6-T7 1.29 t(170) = 7.83;  
P , 0.001
MCI 70–74 T6-T1 3.36 t(32) = 18.01;  
P , 0.001
T6-T7 3.03 t(32) = 7.83;  
P , 0.001
75–89 T6-T1 3.40 t(59) = 8.78;  
P , 0.001
T6-T7 2.61 t(58) = 10.07; 
P , 0.001
AD 70–74 T6-T1 2.06 t(16) = 4.35;  
P , 0.001
T6-T7 3.24 t(16) = 7.78; 
P , 0.001
75–89 T6-T1 2.48 t(74) = 11.40; 
P , 0.001
T6-T7 3.28 t(74) = 14.42; 
P , 0.001
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease.
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applied to the values. There was a significant main effect of 
the pathology group (F [1,220] = 70.5; P , 0.001), and trial 
(F [6,1320] = 110.3; P , 0.001), but not of the age group 
(F [1,220] = 0.254; P = 0.615). As revealed in the figure, 
performance was lower for the AD group than for the MCI 
participants, and performance monotonically increased along 
trials 1–6 and decreased in the delayed (seventh) trial. The 
first-order interaction between pathology group and trial was 
significant (F [6,1320] = 6.62; P , 0.001); the functions in 
Figure 1 show that the rate of performance increase as a func-
tion of the trial was slower for the AD group. However, the 
first-order interactions of the age group were not significant, 
nor was the trial (F [6,1320] = 0.658; P = 0.684), or the pathol-
ogy group (F [1,220] = 3.487; P = 0.063); in the same vein, 
the second-order interaction (pathology group by age group by 
trial) was not significant (F [6,1320] = 0.628; P = 0.708).
When adding the years of education as a   covariate, 
it did not explain a significant part of the variance   
(F [1,137] = 0.018; P = 0.894), and the interaction with trial 
was not significant (F [6,822] = 1.683; P = 0.122). However, 
the effects highlighted (pathology group, trial, and the pathol-
ogy group by trial interaction) remained significant when the 
covariate was years of education.
Again taking decline of performance as a dependent 
variable, a 2 × 2 ANOVA (two pathology groups, two age 
groups) was performed. The results show no significant effect 
of the main factors age group (F [1,220] = 0.318; P = 0.573), 
pathology group (F [1,220] = 1.617; P = 0.205), nor of the 
interaction (F [1,220] = 1.264; P = 0.262). The decline was 
statistically equivalent for the two pathology groups and 
age levels.
The lower panel of Table 3 shows the specific   comparisons 
for the age groups of AD for which we had enough 
  participants. Again, the two age groups showed significant 
gain and delayed decrease. Furthermore, we ran with the first 
trial performance a 2 × 2 ANOVA (two pathology groups, 
two age groups). It did not show significant effects for either 
age group (F [1,181] = 2.60; P = 0.109) or the interaction   
(F [1,181] = 2.66; P = 0.105), but showed a significant effect 
of the pathology group (F [1,181] = 28.89; P , 0.001); as 
expected, the direction of the effect was that AD participants 
showed a lower performance than MCI participants (2.24 vs 
3.59, respectively).
The Verbal Memory Learning Potential 
test as a diagnostic tool
The average values from Figure 1 suggest that the learning 
test employed could be a useful tool for quick classification 
or screening to discriminate between healthy individuals 
and AD patients. Especially interesting is the fact that the 
only group that showed lower performance in the delayed 
trial (trial 7) than in the first learning trial (trial 1) was the 
AD individuals. After checking other combinations, the best 
tool was found to be the difference between the levels of 
performance in the seventh and first trials (T7-T1). If indi-
viduals are categorized as AD with the criterion of having 
a difference of 0 or negative ((T7-T1) #0), the sensitivity 
for the 70–74 age group equals 0.824 (14/17), whereas the 
specificity equals 0.918 (168/183). These statistics are about 
the same in the 75–89 age group, as sensitivity is 0.813 
(61/75) and specificity is 0.917 (88/96). However, there were 
insufficient participants for this same calculation to be done 
in other age groups.
In short, the difference between performance in the 
delayed (seventh) trial and the first trial can be used as 
a simple diagnostic tool, at least in the interval of ages 
between 70 and 89 years. Classifying as AD those who do 
not show better performance in trial 7 compared with their 
  performance in trial 1 (T7-T1 # 0) yields a good balance 
between se  nsitivity and specificity.
Assessing the impact of disease  
in terms of normal aging
This section considers how the association of impairment 
with pathology can be expressed in units that can be more 
easily understood. Specifically, a comparison between 
  Figure 1A–C, allows us to ask the following question: can 
the performance of the MCI and AD groups be placed some-
where on a continuum of decline in normal   individuals? Or, in 
other words, could the impairment associated with the pathol-
ogy be converted (translated) into years of normal decline? 
How many years of normal impairment are equivalent to 
the impairment associated to the pathology, when both are 
reflected in a single measure?
In order to analyze the impact of pathology (MCI and AD) 
in terms of the impact of age, we adjusted some regression 
models. In the final model, performance in the 6th trial was 
the dependent variable, and age (not grouped) plus the years 
of education and two dummy variables that code the pathol-
ogy group, were the independent variables. All independent 
variables were entered in the equation, as all explained a 
significant part of the variance. The final model, for which 
R2 (adjusted) = 0.467, was:
  T6′ =   20.52 − 0.160 ⋅ Age − 2.395 ⋅ MCI − 3.627 ⋅ AD 
+ 0.034 ⋅ YofEd
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Some simple calculations allow estimation of the impact 
of having MCI in the 6th trial in terms of years of normal 
decline. Specifically, dividing the slopes (2.395/0.16) yield that 
having MCI means suffering an impairment in performance 
that is equivalent to the decline of a normal individual during   
15 years; the same analysis for AD (3.627/0.16 = 22.7) yield 
that the impact of being AD is equivalent to 22.7 years of 
normal decline in performance. In other words, the   regression 
model predicts (in trial 6) for an MCI individual the same per-
formance as to a normal individual with 15 years more than 
them; it also predicts for an AD individual the same perfor-
mance as to a normal individual with 22.7 years more than 
them. Of course, the years of education have a positive impact; 
expressed also in a “years of normal decline” metric, the 
impairment that in the average person has associated 1 year 
of normal aging (0.16/0.034) is equivalent to the improvement 
associated to about 5 years of education.
The same does not happen with the delay trial (T6-T7) 
or, in other words, with the interference phenomenon. The 
correlation between age and delay trial performance was 
not significant (R = 0.038; P = 0.287). That is, whereas 
age can account for a decreased gain across the six trials 
and the impact of MCI and AD can be assessed in terms of 
normal aging, the decline associated with the delayed trial 
is not related to normal aging, but both MCI and AD have 
an important impact on it. In other words, the interference 
phenomenon is not an age-based phenomenon but a sign of 
pathology.
Discussion
All age groups of normal individuals show plasticity as 
reflected in performance increases along the six trials of 
verbal learning. The effect of age is clear in the first trial, as 
performance is lower as age increases, and also in the rate of 
learning, as the interaction between trial and the age group 
indicates that people learn at a slower rate the older they are. 
In other words, in terms of plasticity theory1 or dynamic 
assessment,9 “static” assessment of cognitive performance 
as well as learning performance (“dynamic” assessment) are 
both related to age. On the contrary, the drop-in performance 
from the 6th to the 7th (delayed) trial is not associated with 
age but to pathology.
In terms of this pathology, the AD group shows lower per-
formance in the first trial than the MCI and normal individuals 
of the same age; this is a specific qualifier for AD persons. 
The rate of learning for the three groups follows a continuum 
(normal . MCI . AD). The drop-in performance in the 
delayed trial is significantly larger for the two p  athological 
groups; there is no significant difference between them. This 
is a shared qualifier for the pathological groups. Differences 
between normal and AD individuals match the Baltes and 
Raykov2 and Lindenberger and Richeis20 results as well as 
our own previous studies regarding normal, MCI individuals, 
and AD patients.21,23
Regarding our research questions, the first one refers to 
what extent cognitive plasticity, assessed through verbal 
learning, declines across age, including the oldest-old. 
According to our results, all age groups from 55 through 
older than 90 learn from cognitive training and, therefore, 
they show cognitive plasticity as reflected in an increased 
performance along a learning curve of six trials. The effect 
of age is clear in the first trial, as baseline performance is 
lower as age increases, but there is an effect of age in the rate 
of learning as well, as the interaction between the trial and 
the age group indicates that people learn at a slower rate as 
age increases. On the contrary, the strong effect of interfer-
ence showed in the delayed trial (difference of performance 
between trials 6 and 7) is not associated with age but is a 
specific characteristic of the impaired groups.
In sum, our findings provide evidence for differential 
learning performance across aging including the very old, 
and they converge with other studies with young-old1,13,25 
and with the oldest-old.16,20 Regarding learning decline, it is 
important to mention that we did not find significant differ-
ences between two groups: 70–74 years and 75–89 years; 
that is, in our data there is no decline of learning from 70 to 
89 years, as has been reported by Yang et al.16
Regarding our very old nonagenarian participants, their 
decline in learning is significantly higher than that of the other 
age groups, but this age group continues to improve their 
learning performance. This supports the idea that cognitive 
plasticity as demonstrated in the young-old can be extended 
into the oldest-old, as has been reported by Lindenberger 
and Reschies.20 Nevertheless, their performance in learn-
ing is similar to the decline of those younger individuals 
diagnosed as having MCI; that is, they show no significant 
differences in their learning curve with MCI individuals, with 
the exception of the 7th delayed trial. At this point we might 
conclude, as Baltes and Smith15 do, that in spite of the fact 
that they constitute a group of independent nonagenarians, 
they perform as cognitive impaired individuals. Could it be 
considered at the limits of their biological capacity? From 
our point of view, we cannot reach that conclusion; given that 
our group of nonagenarians belongs to a cohort for whom 
mandatory education did not exist (almost half of them have 
no formal education). Even then, our analysis shows that 
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when education is introduced as a covariant, age differences 
between nonagenarians and the other age groups continue to 
be significant. It can be stated that our nonagenarian sample 
is at the limits of their under-stimulated capacities. Ed  ucation 
seems to be a trigger for learning and we must be aware that 
our very old participants had a very low education level, 
which is different from the younger cohorts.
As Terry and Katzman41 proposed, policies have to 
take into consideration the importance of education across 
lifespan. Moreover, the importance of life-long learning 
seems to be a new platform for improving plasticity along life 
and in old age. But it is also important to fight against social 
and group stereotypes which propagate the idea that older 
persons cannot learn or are unable to solve problems.
Also, it is important to investigate to what extent   cognitive 
training across the lifespan and during old age can play a role 
in learning capacities, as pointed out by Mayr.10    Additionally, 
in our data coming from the study of individuals of 90+ years, 
those nonagenarians who are cognitively active (that is, in 
the baseline performed cognitive activities such as “read-
ing”, “playing chess”) show better cognitive functioning in 
the follow-up, after 6–14 months.42 In other words, a new 
panorama is open for the aging mind.
Regarding our second goal, that is, to what extent MCI 
individuals and mild AD patients maintain a certain level of 
plasticity or gradient of modifiability, as in previous stud-
ies, both cognitive-impaired groups show genuine learning. 
Although there are significant differences in learning between 
“normal” and “impaired” groups, MCI and AD individuals 
can modify their performance through cognitive training. 
As expected, the baseline score was significantly lower in 
the AD than in MCI groups. The rate of learning is different 
for the three groups (normal . MCI . AD). But the decline 
of performance in the delayed trial is significantly larger for 
the two pathological groups. Moreover, there is no difference 
between them; this is a shared qualifier for the pathologi-
cal groups. Finally, not showing higher performance in the 
delayed trial than in the first trial can be used as a quick 
diagnostic or screening tool for AD.21,23
Regarding cognitive plasticity shown by MCI and AD 
groups, it can be concluded that although they show lower 
performance, both in the pre-test and in the gain scores, than 
“normal” individuals (with the exception of the similarities 
between the oldest-old and the MCI group) both groups 
reach (after the training) twice the number of words recalled 
than on the first trial: both groups show the ability to learn. 
These results are in accordance to Schreiber and Schneider,43 
who indicate that plasticity-oriented information given in a 
pre-test-training-post-test-design is potentially useful for the 
pu  rposes of early identification of dementia, and to Linden-
berg and Reschies,20 who found that mildly demented indi-
viduals, with a lower baseline that those “normal” in  dividuals, 
show similar gains through learning.
Our results regarding the interference phenomenon 
show that a lower score in trial 7 than in trial 1 (a kind of 
“de-learning” effect), is a result specific to the AD group. 
It constitutes a clear and pathognomonic indicator of 
dementia, even though delay trial performance in the MCI 
group also showed significant differences with any other 
group (including the very old). This result is in accordance 
to the Petersen’s group,18 who found differences between 
nonagenarian demented, with MCI and “normal,” just in 
the delay trials, which is an indicator of neuropsychological 
pathology. Nevertheless, it is important to emphasize that 
mild AD patients can take benefit from learning, as already 
indicated.24 Any nihilistic position concerning these patients 
does not have empirical support; with balanced objectives, 
they can be trained and take benefit from learning.44
Finally, taking into consideration that both age and 
pathology are accounting for cognitive plasticity variance, 
our third question refers to the relative weights of both inde-
pendent variables. Since pathology is associated with age, it 
is difficult to disentangle both factors. Moreover, our MCI 
and AD samples are both younger (age range 55–90 years) 
than our total age range of “normal” sample (55–102 years) 
and have both nonsignificant but higher and homogenous 
levels of education. Nevertheless, our analyses support the 
hypothesis that the effect of having MCI or AD have weights 
equivalent to 15 and 22.7 years of normal aging, respectively. 
In the same vein, 1 year of reverse normal aging seems to 
be equivalent to the improvement associated with about   
5 years of education.
Although theories of aging postulate a non-arithmetic 
aging decline process, at least in biological aging,45,46 our 
analysis assumes that the decline maintains a constant 
rate from 55 through 102 years, as also assumed by Terry 
and Katzman,41 when they established synaptic density 
changes through normal aging. But we are aware of the 
weaknesses of our calculations, which must be considered 
as an attempt to disentangle age, pathology, and education 
in non-representative samples of “normal” individuals 
from 55 through 102 years (who were not assessed from 
neuropsychological perspectives), and clinical MCI and 
AD samples.
Nevertheless, it is important to emphasize the limit of 
these results, already mentioned in our ‘Participants’ section; 
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since we are re-analyzing four studies (two population and 
two clinical studies), although measures and procedures are 
identical for assessing cognitive plasticity, our criteria for 
inclusion are not exactly the same (those “healthy” individu-
als and 90+ years and older). Perhaps this fact could justify 
the broad differences in cognitive plasticity between the 90+ 
and 75–89 years groups.
In conclusion, plasticity or learning capacities is present 
across old age, even in nonagenarian elders, but this plasticity 
declines through the normal aging process. MCI individuals 
and those with AD also show plasticity in the sense that they 
can improve their memory performance through learning. 
Nonagenarian individuals show a similar learning curve 
to those of MCI patients. “Normal” individuals from 55 
through 89 years significantly differ in their learning curves 
from both pathological groups. Those pathological groups 
significantly differ from “normal” groups in the interfer-
ence phenomenon. This effect is dramatic in AD patients; a 
“de-learning”effect appeared only in those individuals as a 
pathognomonic sign.
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